BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors
("SV"), a leading global health care investment firm, is pleased to
announce a series of realizations from its growth equity
portfolio:
On August 6, HillRom (NYSE: HRC)
completed the acquisition of SV's portfolio company Bardy
Diagnostics ("BDx"). In 2016, SV partnered with founder
Dr. Gust Bardy to support the commercial launch of the Carnation
Ambulatory Monitor, a best-in-class ambulatory cardiac monitor. The
CAM offers both superior patient convenience and improved data
capture. During the course of SV's partnership with BDx, the
company built an increasingly sophisticated services capability and
grew revenue ten-fold. SV wishes the BDx team continued
success under the HillRom umbrella.
SV portfolio company Healthify agreed to be acquired by
WellSky on July 29. SV invested in
Healthify in 2019 following extensive research into social
determinants of health, the impact of access to food, housing, and
childcare on health outcomes. Healthify's technology and
networks integrate social services into the clinical
ecosystem. SV extends its congratulations to co-founder and
CEO Manik Bhat and the entire
mission-focused team at Healthify.
Also on July 29, Bioventus
(NASDAQ: BVS) announced a definitive agreement to acquire SV
portfolio company Misonix in a cash and stock transaction.
SV's involvement began in 2017 when it invested in Solsys and its
leading cellular and tissue-based products for regenerative wound
healing. Two years later, Misonix acquired Solsys to augment its
surgical and wound care solutions platform; SV joined the Misonix
board of directors. The recently announced Bioventus / Misonix
combination will build broad capabilities across the spine, lower
extremity, and wound care markets. SV thanks Misonix CEO
Stavros Vizirgianakis and Solsys
co-founders Allan Staley and
Guy Levy for their commitment to
patients and shareholders.
These realizations further validate SV's growth equity strategy
of partnering with founders and executives and their
commercial-stage companies to drive growth and deliver solutions
that broaden patient access, improve health outcomes, and lower
costs. SV believes that the growing adoption of technology by
the U.S. health care industry will enable and accelerate this
mission.
About SV Health Investors
SV Health Investors is a leading healthcare fund manager with
$2.6B assets under management. The SV
family of funds invests across stages, geographic regions and
sectors, with expertise spanning healthcare services / technology,
medical products, biotechnology, dementia and public
equities. SV Growth Fund is sector-focused and thesis-driven
to seize opportunities and address the most pressing industry
challenges by providing growth capital and liquidity for industry
leaders transforming healthcare. For more information, please see
www.svhealthinvestors.com.
Media contact:
Dana O'Brien
SV Health Investors
dobrien@svhealthinvestors.com
View original
content:https://www.prnewswire.com/news-releases/sv-health-investors-announces-three-realizations-in-its-growth-equity-portfolio-301358482.html
SOURCE SV Health